Alexion Pharmaceuticals (ALXN) was Reiterated by FBR & Co. to “Underperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 92 from a previous price target of $82 . FBR & Co. advised their investors in a research report released on Sep 16, 2016.
Many Wall Street Analysts have commented on Alexion Pharmaceuticals. FBR & Co. Initiated Alexion Pharmaceuticals on Sep 15, 2016 to “Underperform”, Price Target of the shares are set at $82.Shares were Reiterated by Stifel on Jul 29, 2016 to “Buy” and Lowered the Price Target to $ 182 from a previous price target of $195 .Shares were Reiterated by Barclays on Jul 29, 2016 to “Equal Weight” and Lowered the Price Target to $ 150 from a previous price target of $165 .
On the company’s financial health, Alexion Pharmaceuticals reported $1.13 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus of $1.17. The company had revenue of $753.10 million for the quarter, compared to analysts expectations of $743.05 million. The company’s revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.44 EPS.
Alexion Pharmaceuticals opened for trading at $126.91 and hit $130.39 on the upside on Wednesday, eventually ending the session at $129.42, with a gain of 2.07% or 2.63 points. The heightened volatility saw the trading volume jump to 969,888 shares. Company has a market cap of $29,022 M.
In a different news, on Sep 14, 2016, Carsten Thiel (EVP, Chief Commercial Officer) sold 3,225 shares at $126.60 per share price. According to the SEC, on Sep 9, 2016, Edward Miller (SVP, Chief Compliance Officer) sold 367 shares at $128.32 per share price. On Sep 2, 2016, Julie O’neill (EVP. Global Operations) sold 650 shares at $126.29 per share price, according to the Form-4 filing with the securities and exchange commission.
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.